Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC  Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100MCumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC PortfolioCo-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of DirectorsAadi to Hold Webcast and ...